Immunotherapy of asthma and allergic diseases

Current Opinion in Pediatrics

Volumn 12, Issue 6, 2000, Pages 574-578

  TePas, Elizabeth C ^a   Umetsu, Dale T ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; DNA VACCINE; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGENICITY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REMISSION; REVIEW; SENSITIZATION; TREATMENT OUTCOME;

ASTHMA; CHILD; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY;

EID: 0033738870     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200012000-00011     Document Type: Review

References (58)

1. The prevalence and medical and economic impact of allergic rhinitis in the United States
2. The inverse association between tuberculin responses and atopic disorder
3. Relative scarcity of asthma and atopy among rural adolescents raised on a farm
4. Exposure to foodbourne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: Epidemiological study
5. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children
6. Association of asthma with serum IgE levels and skin-test reactivity to allergens
7. Asthma and wheezing in the first six years of life
8. Allergen immunotherapy: Therapeutic vaccines for allergic disease: WHO position paper
9. Effectiveness of specific immunotherapy in the treatment of asthma: A meta-analysis of prospective, randomized, double-blind, placebo-controlled studies
10. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: A meta-analysis
11. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: An analysis of randomized, prospective, single- or double-blind, placebo-controlled studies
12. Long-term clinical efficacy of grass-pollen immunotherapy
13. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children
14. PAT - The Preventive Allergy Treatment Study design and preliminary results
15. Fatalities from immunotherapy (IT) and skin testing (ST)
16. Survey of fatalities from skin testing and immunotherapy 1985-1989
17. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany
18. Grass pollen immunotherapy decreases the number of mast cells in the skin
19. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy
20. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for PhI p 1, a major grass pollen allergen
21. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals
22. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma
23. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis
24. Low dose of orally administered antigen downregulates the T helper type 2-response in a murine model of dust mite hypersensitivity
25. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation
26. Intranasal exposure to protein antigen induces immunologic tolerance mediated by functionally diabled CD4+ T cells
27. Systemic immunologic changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy
28. Mechanisms preventing allergen-induced airway hyperreactivity: Role of tolerance induction and immune deviation
29. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells
30. Interleukin-10 gene transfer to the airway regulates allergic mucosal sensitization in mice
31. CD4+ T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation
32. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial
33. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judacia extract in children with allergic rhinoconjunctivitis
34. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients
35. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: A double-blind study
36. A multicenter trial of specific local nasal immunotherapy
37. Pepsin-digested peanut contains T-cell epitopes but no IgE epitopes
38. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: Contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2
39. Determination of the N- and C-terminal sequences required to bind human IgE of the major house dust mite allergen Der f 2 and epitope mapping for monoclonal antibodies
40. The safety and efficacy of ALLERVAX CAT in cat allergic patients
41. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production
42. Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia
43. Heat killed Listeria monocytogenes as an adjuvant converts established Th2-dominated immune responses into Th1-dominated responses
44. Vaccination with heat-killed Listeria as adjuvant reverses established allergen-induced airway hyperreactivity and inflammation: Role of CD8+ T cells and IL-18
45. DNA vaccines - Designer vaccines for the 21st century
46. The role of CpG motifs in innate immunity
47. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
48. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization
49. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization
50. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
51. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
52. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
53. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
54. Oligodeoxynucleotides containing CpG motifs modulate the allergic Th2 response of BALB/c mice to Bet v 1, the major birch pollen allergen
55. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator
56. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group
57. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
58. Anti-IgE as novel therapy for the treatment of asthma